Colon Cancer Prevention
Conditions
Brief summary
A Phase 1B study of the efficacy of a topically-administered 7-amino acid peptide labeled with a near-infrared fluorophore Cy5 for detecting neoplastic areas of the colon is proposed. The study will test the efficacy of administering this agent (QRH-882260 Heptapeptide) to human subjects undergoing clinically-indicated colonoscopy for endoscopic resection of known colonic adenomas or for surveillance biopsies of known dysplasia in the setting of irritable bowel disease (IBD). Up to 120 evaluable subjects will be enrolled. Subjects will be recruited around scheduled standard of care procedures. The endoscopists performing the procedures are all endoscopists credentialed at the University of Michigan to do these procedures. Urine for dipstick pregnancy testing (if applicable) will be collected before the procedure, along with medical information. Vital signs are routinely monitored throughout the clinical procedure and are available in the electronic medical record. The endoscopy will proceed per the University of Michigan Health System (UMHS) standard of care. The endoscopist performing the clinical procedure will evaluate the potential risk (if any) for the subject to continue with the procedure or study. Five mL of the reconstituted QRH-882260 Heptapeptide (\ 100 μM) will be sprayed onto the site of interest through a catheter in the endoscope. Five minutes after QRH-882260 Heptapeptide application, the unbound peptide will be washed off using the endogator irrigator and the residual liquid will be suctioned. Pictures with white-light and fluorescence will be taken with the scanning fiber based molecular imaging endoscopic probe inserted via the instrument channel of the standard endoscope before the QRH-882260 Heptapeptide application, immediately after application and then again after the QRH-882260 Heptapeptide will be washed off. The area of interest identified will be resected/biopsied per discretion of the endoscopist per clinical care. All specimens taken are for clinical care only (not research use) and will be sent for routine histology per UMHS standard of care.
Interventions
topical spray; fluorescently-labeled peptide composed of a 7-amino acid sequence \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a 5 amino acid linker \[Gly-Gly-Gly-Ser-Lys\] to a near-infrared fluorophore, Cy5. The complete peptide sequence is written as: Gln-Arg-His-Lys-Pro-Arg-Glu-Gly-Gly-Gly-Ser-Lys(Cy5)-NH2, and is abbreviated as: QRHKPRE-GGGSK-(Cy5)-NH2.
DEVICEScanning Fiber Endoscope
Endoscope used for providing the light via laser to image the area of interest in the colon after the QRH has been sprayed and rinsed.
Sponsors
Danielle Kim Turgeon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
Subject meets at least one of the following criteria: * At increased risk for colorectal cancer (CRC) and colonic polyps * Known colonic adenomas scheduled for colonic resection * Scheduled for outpatient colonoscopy for follow up surveillance of IBD with known dysplasia or who are at high risk for high grade dysplasia * Subject is scheduled for outpatient colonoscopy in the Medical Procedures Unit at UMHS * Subject is medically cleared for the procedure (e.g. washout for anticoagulants, co-morbidities) Standard practice guidelines for safely proceeding with the procedure will be sufficient for the study * Age 18 to 100 years * Willing and able to sign informed consent
Exclusion criteria
Subjects with known allergy or negative reaction to Cy5 (a near-infrared fluorophore) or derivatives * Subjects on active chemotherapy or radiation treatment * Pregnant or trying to conceive
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of QRH-882260 Heptapeptide administration-related adverse events | 1 year | Continued monitoring of safety in subjects as measured by the number of Adverse Event (AE) assessments, severity (grade), and relationship to the study drug (any that could be related). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of QRH-882260 Heptapeptide administration for detection of polypoid and non-polypoid colonic neoplasia | 1 year | The test product efficacy will be assessed by evaluating the fluorescence intensified measured from suspicious regions of colonic mucosa where the fluorescently-labeled peptide (QRH-882260) is administered. Measurement of peptide binding will be evaluated by the fluorescence intensity measured from the suspicious (target) region and normal tissues (background) to produce a target-to-background ratio. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of QRH-882260 Heptapeptide administration for detection of dysplasia in the setting of IBD | 1 year | The test product efficacy will be assessed by evaluating the fluorescence intensified measured from suspicious regions of colonic mucosa where the fluorescently-labeled peptide (QRH-882260) is administered. Measurement of peptide binding will be evaluated by the fluorescence intensity measured from the suspicious (target) region and normal tissues (background) to produce a target-to-background ratio. |
Countries
United States
Outcome results
None listed